Perspective Therapeutics insider purchases 11,000 CATX shares on Form 4

Rhea-AI Filing Summary

Perspective Therapeutics, Inc. (CATX) reported an insider stock purchase by its Chief Accounting Officer on a Form 4. On 11/13/2025, the officer acquired 11,000 shares of common stock in an open market transaction coded “P” for purchase. The weighted average price paid was $2.0268 per share, with individual trades executed in a range from $2.0235 to $2.0300. Following this transaction, the officer beneficially owns 59,800 shares of Perspective Therapeutics common stock held directly.

Insider Trade Summary

Net Buyer: 11,000 shares

Net Buy 1 txn

Insider Hunt Jonathan Robert

Role Chief Accounting Officer

Bought 11,000 shs ($22K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	11,000	$2.0268	$22K

Holdings After Transaction: Common Stock — 59,800 shares (Direct)

Footnotes (1)

1. F1. The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.0235 to $2.0300, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the transactions described in this footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 11/17/2025 - 08:01 AM Learn about SEC filing dates

FAQ

What insider transaction did Perspective Therapeutics (CATX) disclose on this Form 4?

The filing reports that the Chief Accounting Officer of Perspective Therapeutics, Inc. (CATX) purchased 11,000 shares of the company’s common stock in an open market transaction.

On what date did the CATX insider purchase shares and at what price?

The CATX officer purchased the shares on 11/13/2025 at a weighted average price of $2.0268 per share, with individual trades between $2.0235 and $2.0300.

How many Perspective Therapeutics (CATX) shares does the insider own after this transaction?

After the reported purchase, the Chief Accounting Officer beneficially owns 59,800 shares of Perspective Therapeutics common stock, held directly.

What does the weighted average price mean in this CATX Form 4 filing?

The weighted average price of $2.0268 reflects that the 11,000 shares of CATX stock were bought in multiple trades at prices from $2.0235 to $2.0300, averaged by share volume.

What type of transaction code appears in the Perspective Therapeutics Form 4?

The transaction is coded “P”, which indicates an open market or private purchase of Perspective Therapeutics (CATX) common stock by the reporting person.

What is Form 4 in relation to Perspective Therapeutics (CATX)?

Form 4 is an SEC filing used by company insiders of Perspective Therapeutics (CATX) to report changes in their beneficial ownership of the company’s securities, such as stock purchases or sales.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hunt Jonathan Robert

(Last) (First) (Middle)

C/O PERSPECTIVE THERAPEUTICS, INC.

2401 ELLIOTT AVENUE, SUITE 320

(Street)

SEATTLE WA 98121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Perspective Therapeutics, Inc. [ CATX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/13/2025		P		11,000	A	$2.0268(1)	59,800	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.0235 to $2.0300, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price in the transactions described in this footnote.

	/s/ Jonathan Hunt by Chris Nenno, as Attorney-in-Fact	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.